Sight Sciences (Sight Sciences) ROCE % : -40.35% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sight Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sight Sciences's annualized ROCE % for the quarter that ended in Mar. 2024 was -40.35%.

Sight Sciences ROCE % Historical Data

The historical data trend for Sight Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sight Sciences ROCE % Chart

Sight Sciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-167.12

-74.18

-35.38

-35.39

-28.62

Sight Sciences Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial														-33.50	-30.38	-27.64	-23.57	-40.35

Sight Sciences ROCE % Calculation

Sight Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-50.029	/	( ( (213.073 - 17.817)	+	(166.651 - 12.252) )	/ 2 )
	=	-50.029	/	( (195.256	+	154.399)	/ 2 )
	=	-50.029	/	174.8275
	=	-28.62 %

Sight Sciences's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-60.18	/	( ( (166.651 - 12.252)	+	(155.56 - 11.693) )	/ 2 )
	=	-60.18	/	( ( 154.399	+	143.867 )	/ 2 )
	=	-60.18	/	149.133
	=	-40.35 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Sight Sciences (NAS:SGHT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sight Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of Sight Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sight Sciences (Sight Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sight Sciences Inc (NAS:SGHT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.sightsciences.com

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Executives

Jeremy B. Hayden	officer: Chief Legal Officer	2 MUSICK, 2 MUSICK, IRVINE CA 92618
Sam Boong Park	officer: Chief Operating Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Paul Badawi	director, 10 percent owner, officer: President and CEO	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
David Badawi	director, officer: Chief Technology Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
D1 Capital Partners L.p.	10 percent owner	9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Staffan Encrantz	director	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Matthew Link	officer: Chief Commercial Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Catherine Mazzacco	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Alison Bauerlein	officer: See remarks	326 BOLLAY DRIVE, GOLETA CA 93117
James Rodberg	officer: See Remarks	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK CA 94025
Tamara Fountain	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Brenda Jane Larsen-becker	director	C/O SIGHT SCIENCES, INC., 3000 SAND HILL ROAD, BUILDING 3, STE 105, MENLO PARK CA 94025
Jesse Selnick	officer: Chief Financial Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Daniel S. Sundheim	10 percent owner	C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Erica J. Rogers	director	C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089